Pediatric Transplantation · 2013 · 18 citations · 8 references
MedicineHematologyPediatricsMonoclonal AntibodiesPediatric HematologyStem Cell TransplantationDonor-specific AntibodiesHematopoietic Stem Cell Transplant PharmacotherapyImmunosuppressionImmunosuppressive TherapyPediatric Clinical ImmunologyAllogeneic Transplant PharmacotherapyDonor-specific Antibody ManagementDyskeratosis CongenitaHematopoietic Stem Cell Transplantation ImmunotherapyImmunomodulatory BiologicsTransplant Immunology In Children
AIHA following allogeneic HSCT is appearing more frequently in the literature. It occurs as a result of donor cell-derived antibodies targeting donor red cell antigens. Little guidance exists on the management of such patients, particularly in the pediatric setting. First-line conventional treatment is corticosteroids and/or immunoglobulin therapy with monoclonal antibody therapy reserved for treatment failure. We report our experience of a child refractory to immunoglobulin and steroid therapy who required several infusions of rituximab and immunomodulatory therapy to obtain a clinically significant response.
8
Tracey O’Brien, Ted Eastlund, Charles Peters et al. · British Journal of Haematology · 2004 · 100 citations · Full text